Here are three facts:
1. Signafuse received FDA 510(k) clearance in 2014 as bone void filler for standalone use in posterolateral spine fusion procedures.
2. Signafuse is a moldable bone graft comprised of patented bioactive glass particles and biphasic mineral granules suspended in a patented resorbable polymer carrier.
3. BioStructures is a medical device company focused on developing proprietary platforms in bioresorbable bone graft products for a range of spinal and orthopedic fusion procedures.
More articles on devices:
NuVasive reaches definitive settlement with US: 5 points
Is Stryker next for a big transaction? 7 key notes
Amendia acquires Custom Spine — 5 key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
